MILITARY PHARMACY AND MEDICINE

© Military Pharmacy and Medicine • 2012 • 4 • 14 – 16References:Review article1. Nowak JZ: [Dry form AMD – do we know how totreat it?]. Mag Lek Okul. 2011; 5: 44–8.2. Nowak JZ: [Ophthalmic antioxidantpreparations: a survey and supportive argumentsfor their use in AMD]. Mag Lek Okul. 2010; 4:185–98.3. Nowak JZ: [Omega-3 polyunsaturated fatty acidsin retina and medical practice – pros and cons].Mag Lek Okul. 2009; 3: 208–20.4. Nowak JZ: Age-related macular degeneration(AMD): pathogenesis and therapy. PharmacolRep. 2006; 58: 353–63.5. Nowak JZ: [In search of biomarkers for agerelatedmacular degeneration (AMD)]. Mag LekOkul. 2009; 3: 132–43.6. Nowak JZ: [Role of lipofuscin in pathogenesisof age-related macular degeneration (AMD)].Magazyn Okulistyczny. 2005, 2: 103–14.7. Nowak JZ: [Drusens, basal deposits, inflammationand age-related macular degeneration(AMD)]. Magazyn Okulistyczny. 2005; 2: 174–86.8. Nowak JZ: [Inflammation: acute, chronic andpara-inflammation – new ideas, new drugs]. MagLek Okul. 2011; 5: 194–211.9. Bhutto I, Lutty G: Understanding age-relatedmacular degeneration (AMD): relationshipsbetween the photoreceptor/retinal pigmentepithelium/Bruch’s membrane/choriocapillariscomplex. Mol Aspects Med. (2012); 33: 295-317.10. Fine SL, Berger JW, Maguire MG, Ho AC: Agerelatedmacular degeneration. N Engl J Med.2000; 342: 483–92.11. McConnell V, Silvestri G: Age-related maculardegeneration. Ulster Med J. 2005; 74: 82–92.12. Klaska I, Nowak JZ: [The role of complement inphysiology and pathology]. Post Hig Med Dosw(Online). 2007; 61: 167–77.13. Anderson DH, Radeke MJ, Gallo NB, ChapinEA, Johnson PT, Curletti CR et al.: The pivotalrole of the complement system in aging andage-related macular degeneration: hypothesis revisited.Prog Retin Eye Res. 2010; 29: 95–112.14. Wiktorowska-Owczarek A, Nowak JZ: [AMDand oxidative stress. 1. The analysis of factorsinfluencing the generation of reactive oxygenspecies in the retina]. Mag Lek Okul. 2008; 2:200–4.15. Wiktorowska-Owczarek A, Nowak JZ: [Luteinand zeaxanthin – two carotenoids serving theprotection against age-related macular degeneration(AMD)]. Okulistyka. 2004; 7: 29–34.16. Wiktorowska-Owczarek A, Nowak JZ: [AMDand oxidative stress. 2. The analysis of componentsof pharmaceutical preparations used inprophylaxis of AMD]. Mag Lek Okul. 2008; 2:205–12.17. Wiktorowska-Owczarek A, Nowak JZ: [Pathogenesisand prophylaxis of AMD: focus on oxidativestress and antioxidants]. Postepy Hig MedDosw (online). 2010; 64: 333–43.18. Nowak JZ: [Age-related macular degenerationand immunological system: how muchimmunology is in AMD?]. Mag Lek Okul. 2009;3: 102–14.19. Khoo HE, Prasad KN, Kong KW, Jiang Y, IsmailA: Carotenoids and their isomers: color pigmentsin fruits and vegetables. Molecules. 2011; 16:1710–38.20. Sommerburg O, Keunen JE, Bird AC, van KuijkFJ: Fruits and vegetables that are sources forlutein and zeaxanthin: the macular pigment inhuman eyes. Br J Ophthalmol. 1998; 82: 907–10.21. Nebeling LC, Forman MR, Graubard BI, SnyderRA: Changes in carotenoid intake in the UnitedStates: the 1987 and 1992 National HealthInterview Surveys. J Am Diet Assoc. 1997; 97:991–6.22. Nebeling LC, Forman MR, Graubard BI, SnyderRA: The impact of lifestyle characteristics oncarotenoid intake in the United States: the 1987National Health Interview Survey. Am J PublicHealth. 1997; 87: 268–71.23. Nowak JZ, Koszela K: [Eylea TM (VEGF-Trap-Eye) – New „antiVEGF” drug: therapeuticapplications and significance for the Avastin-Lucentis dilemma]. Mag Lek Okul. 2011; 5:324–36.24. Loane E, Kelliher C, Beatty S, Nolan JM: Therationale and evidence base for a protective roleof macular pigment in age-related maculopathy.Br J Ophthalmol. 2008; 92: 1163–8.25. Bone RA, Landrum JT, Mayne ST, Gomez CM,Tibor SE, Twaroska EE: Macular pigment indonor eyes with and without AMD: a casecontrolstudy. Invest Ophthalmol Vis Sci. 2001;42: 235–40.26. Bernstein PS, Zhao DY, Wintch SW, Ermakov IV,McClane RW, Gellermann W: Resonance Ramanmeasurement of macular carotenoids in normalsubjects and in age-related macular degenerationpatients. Ophthalmology. 2002; 109: 1780–7.27. Obana A, Hiramitsu T, Gohto Y, Ohira A,Mizuno S, Hirano T et al.: Macular carotenoidlevels of normal subjects and age-relatedmaculopathy patients in a Japanese population.Ophthalmology. 2008; 115: 147–57.28. Sabour-Pickett S, Nolan JM, Loughman J,Beatty S: A review of the evidence germaneto the putative protective role of themacular carotenoids for age-related maculardegeneration. Mol Nutr Food Res. 2011; 55: 1-17.29. Sabour-Pickett S, Nolan JM, Loughman J,Beatty S: A review of the evidence germaneto the putative protective role of themacular carotenoids for age-related maculardegeneration. Mol Nutr Food Res. 2012; 56:270–86.30. Kanis MJ, Berendschot TT, van Norren D: Influenceof macular pigment and melanin on inci-14 http://military.isl-journals.com